Product: Rimantadine (hydrochloride)
CCL2/MCP1 Blocking Peptide Summary
| Description |
A peptide to CCL2.
|
| Immunogen |
Synthetic peptide made to an internal portion of rat MCP1 (within residues 30-80). [Swiss-Prot# P14844]
|
| Specificity |
This peptide is specific for NBP1-07034 only.
|
| Protein/Peptide Type |
Blocking Peptide
|
| Gene |
CCL2
|
Applications/Dilutions
| Application Notes |
This peptide is useful as a blocking peptide for NBP1-07034.For further blocking peptide related protocol, click here.
|
Packaging, Storage & Formulations
| Storage |
Store at -80C. Avoid freeze-thaw cycles.
|
| Buffer |
Peptide dissolved in dH2O. Contains no BSA.
|
| Preservative |
No Preservative
|
| Concentration |
1.0 mg/ml
|
Alternate Names for CCL2/MCP1 Blocking Peptide
- C-C motif chemokine 2
- chemokine (C-C motif) ligand 2
- GDCF-2
- HC11Monocyte secretory protein JE
- MCAFMonocyte chemotactic and activating factor
- MCP1 Monocyte chemotactic protein 1
- MCP-1 Small-inducible cytokine A2
- MGC9434
- Monocyte chemoattractant protein 1
- monocyte chemoattractant protein-1
- SCYA2HSMCR30
- small inducible cytokine A2 (monocyte chemotactic protein 1, homologous tomouse Sig-je)
- small inducible cytokine subfamily A (Cys-Cys), member 2
- SMC-CF
Background
MCP-1 (monocyte chemoattracctant protein-1, also called C-C motif chemokine 2 or CCL2) is a secreted protein belonging to intercrine beta (chemokine CC) family and it specifically act as a chemotactic factor to attracts monocytes, CD4+ T cells, NK cells as well as for CCR2 expressing cells, but not neutrophils. Both hematopoietic and non-hematopoietic cells that include monocytes/macrophages, dendritic cells, astrocytes, endothelial cells and fibroblasts express MCP-1, and monocytes/macrophages are the major source of MCP-1 in peripheral blood. Besides, expression at acute inflammation sites, MCP-1 is upregulated in chronic inflammation, including autoimmune disease, atherosclerosis, cancer, and chronic infection. MCP-1 has been implicated in both pro-inflammatory and anti-inflammatory responses, and is a potential intervention point for the treatment of various inflammatory/autoimmune diseases (multiple sclerosis, atherosclerosis, insulin-resistant diabetes, rheumatoid arthritis and lupus nephritis), cancers (breast and prostate cancer) and HIV-1/AIDS.